Conferences
Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Hematology
Lymphoma
Leukemia
Lung Cancers
Melanoma
Prostate Cancer
Urology
CLL
Precision Medicine
Supportive Care
More...
Giants Cancer Care

Dr. Brentjens on the Potential Application of CAR-Modified T Cell Technology

Renier J. Brentjens, MD, PhD
Published Online: Thursday, April 24, 2014
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential application of CAR-modified T cell technology.

Brentjens says he is confident that CAR-modified T cell technology will have utility in a far wider array of cancers than just B-cell acute lymphoblastic leukemia (ALL) as researchers and physicians learn more about the immune system, tumor immunology, and target antigens.​

Research is being conducted looking at different receptors for different cancers including acute myeloid leukemia and ovarian cancer.

The answer as to whether this technology has a wider application than just B-cell ALL will be known not after one round of clinical trials, Brentjens says, but as it is adapted to be more specific to tumors and better able to kill tumors.

Online CME Activities
Free CME from PER
Advances in Multiple Myeloma
Cancer Summaries and Commentaries™: Update from Chicago: Castrate Resistant Prostate Cancer and Advanced Melanoma
Community Practice Connections™: Novel Perspectives in Personalizing EGFR-Targeted Therapy in NSCLC: Frontline and Overcoming Resistance
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Gynecologic Cancers
More Reading
 
$auto_registration$